Ionq Stock Earnings Reports

Key points for investors:

- Record quarter: GAAP revenue of $64.7M in Q1 2026 (755% YoY), the company's largest quarter to date and fourth consecutive record quarter.

- Raised full-year revenue guidance: now $260M–$270M for 2026; Q2 guidance $65M–$68M. Management expects ~100% organic revenue growth for the year.

- Strong backlog / multi‑quarter visibility: Remaining performance obligations (RPO) of $470M as of March 31, 2026 (up ~554% YoY). For every $1 of revenue recognized in Q1, about $2.50 of RPO was added.

- Robust balance sheet and investment capacity: Cash, cash equivalents and investments of $3.1B to fund R&D, scaling and M&A (SkyWater acquisition in process, expected Q2–Q3 close subject to approvals).

- Heavy R&D investment: GAAP R&D of $125.7M in Q1 (up 215% YoY) to support Tempo (Gen-5), 256‑qubit (Gen-6) chip development and future 10k‑qubit plans. SkyWater collaboration has already produced ion trap samples meeting critical metrics for 256‑qubit chips.

- Profitability profile and guidance: Adjusted EBITDA loss of $96.8M in Q1 (would have been ~$85M excluding ~$12M SkyWater commercial agreement expense). Reaffirmed full-year adjusted EBITDA guidance: negative $310M to negative $330M.

- GAAP net income of $805.4M in Q1 driven primarily by a ~$1.1B non‑cash mark‑to‑market warrant valuation (management cautions this is non‑operational/volatile).

- Technical and commercial leadership claims: published a full fault‑tolerant “walking cat” architecture and third‑party validated benchmarks (up to 10k× faster time‑to‑solution for select algorithms). Presold first chip‑based 256‑qubit system; customer commissioning expected by end of Q2 2027. Ongoing work toward 10k‑qubit systems and logical‑qubit scaling toward Q‑Day in the 2028–2029 window.

- Platform expansion and customer traction: ~60% of Q1 revenue from commercial customers, ~35% international, and >33% of revenue from multiproduct customers (buyers of ≥2 product lines). Broad application partnerships in pharma, finance, energy and logistics; deployments of quantum networking (Poland, Switzerland, Romania, Slovakia, new Florida initiative) and federal contracts (DARPA/HARC, Space Development Agency, Missile Defense Agency).

- Key risks/considerations: continued high R&D and development spend, near‑term negative EBITDA, potential volatility from warrant valuations, execution risk on manufacturing scale and regulatory approvals for SkyWater transaction.

Bottom line: IonQ reported a major commercially oriented quarter with strong top‑line growth, expanded backlog and a large cash runway to accelerate R&D and scaling. Investors should weigh the rapid revenue and backlog growth and technology milestones against continued negative EBITDA, elevated R&D spending, and execution risk as the company scales manufacturing and delivers larger systems.